FGF21 analog LY2405319 (Lilly), the first to enter a phase 1 clinical trial, showed promising metabolic outcomes in preclinical studies in mice and monkeys on features of T2D (124, 139, 140). Here, FGF21 is linked to type 2 diabetes mellitus.